Disease-modifying treatments for major neurocognitive disorders, including Alzheimer’s disease, Parkinson’s disease and other cognitive deficits, are among the main unmet needs in modern medicine.

Next-gen weight-loss drugs like CagriSema and UBT251 could hit shelves within a year, promising more effective obesity and diabetes treatments.

Novo Nordisk is licensing rights to a United Biotechnology drug that sparks metabolic effects by binding to and activating receptors for GLP-1, GIP, and glucagon. Separately, the pharma giant said ...

Opko Health and Entera Bio have formalized their partnership as the biotechs prepare to take the first orally administered dual agonist glucagonlike-peptide 1 (GLP-1)/glucagon peptide into the clinic.

CHICAGO, March 17, 2025--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing ...

The U.S. Centers for Disease Control and Prevention is closely monitoring an unknown disease that has killed dozens in the Democratic Republic of Congo, the agency said in a statement on Tuesday ...

D&D Pharmatech, Inc. (D&D) (KOSDAQ: 347850), a clinical-stage biotechnology company focused on the development of disease-modifying drugs, tod ...

Parkinson's disease (PD) is a common neurodegenerative disease. Glucagon-Like-Peptide-1 (GLP-1) receptor agonists decrease the incidence of developing PD, and are being considered for the treatment of ...

Article Title. Current Status of Glucagon-like Peptide-1 Receptor Agonists in Metabolic Dysfunction-associated Steatotic Liver Disease: A Clinical Perspective ...

Glucagon-like peptide-1 (GLP-1) receptor agonists (also called “glutides”) are an effective treatment for patients with type 2 diabetes and chronic kidney disease In a randomized controlled trial of ...

The most potent stimuli for glucagon secretion are hypoglycemia, prolonged fasting, exercise, and after a protein-rich meal. Glucagon levels in the blood may rise 3-4-fold with hypoglycemia or ...